Seppic comes to rescue of aging face, bust
This article was originally published in The Rose Sheet
Executive SummaryNoting that with age, "the cheeks become hollow and the chest sags," Paris-based subsidiary of Air Liquide introduces Voluform, a 3D "plumping" active ingredient it says can remodel curves of the face and bust, presenting an alternative to cosmetic surgery and Botox injections. Voluform stimulates "functionality" of adipocytes, or fat cells, and prevents loss of volume and fullness, according to information presented at in-cosmetics. "With its plumping effect, it redefines the contours of the face, fills in wrinkles and rounds out the chest with original tautness and firmness," Seppic says. After one month of topical treatment on the bust area, 83% of testers saw increased breast volume, while 60% recorded an average size increase of 0.6 centimeters. Firm is positioning Voluform as "an active ingredient for each generation.
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.